Homocystinuria due to cobalamin cofactor metabolism (cbl) defect
DBCOND0151379Congenital, Hereditary, and Neonatal Diseases and AbnormalitiesHemic and Lymphatic Diseases
Homocystinuria due to cobalamin cofactor metabolism (cbl) defect is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.
- Classified under
- Indicated drugs
What you can answer from here — as of October 23, 2026
1Indicated drugWith each drug's targets and mechanismListed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not proseSign in
Which approved drugs for Homocystinuria due to cobalamin cofactor metabolism (cbl) defect share a target, and which companies have late-stage candidates against it?
Create a free account or log in to explore the full data card.
Create Account